

Business Courier of Cincinnati - April 19, 2010
[/cincinnati/stories/2010/04/19/daily8.html?ed=2010-04-19](#)

BUSINESS COURIER

Monday, April 19, 2010, 2:44pm EDT

Amylin, partners seek EU drug approval

Business Courier of Cincinnati - by [Craig M. Douglas](#) Courier Contributor

Drug maker **Amylin Pharmaceuticals Inc.**, along with partners **Alkermes Inc.** and Eli Lilly & Co., have filed paperwork with European regulators to commercialize their exenatide therapy for type-2 diabetes patients.

The development is the latest boost for Waltham, Mass.-based Alkermes, Indianapolis-based Lilly and San Diego-based Amylin (NASDAQ: AMLN), which together are developing the extended-release, once-weekly medication to be sold under the brand name Bydureon.

Amylin's West Chester plant manufactures the long-acting release formulation of exenatide, marketed under the brand name Byetta.

On Monday, Alkermes (Nasdaq: ALKS) said the new application for marketing authorization was filed by Eli Lilly (NYSE: LLY) with the European Medicines Agency. The company said Bydureon is not received approval from a regulatory agency to date.

In March, the companies said the **Food and Drug Administration said it had sufficient information to rule on the drug's potential approval in the U.S.**

All contents of this site © American City Business Journals Inc. All rights reserved.